New hope for AML patients: drug added to transplant aims to keep cancer at bay
NCT ID NCT06954987
Summary
This study is testing if adding a drug called venetoclax to a stem cell transplant helps adults with acute myeloid leukemia (AML) stay in remission longer. Participants will receive either venetoclax or a placebo (inactive pill) before and after their transplant. The main goal is to see if the drug improves survival without the cancer returning in the first 100 days after the procedure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.